Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 2 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus LIQUAEMIN LOCK FLUSH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 2 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus LIQUAEMIN LOCK FLUSH.
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER vs LIQUAEMIN LOCK FLUSH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, accelerating its inhibition of coagulation factors IIa (thrombin), Xa, and others, thereby preventing thrombus formation and extension.
Heparin potentiates the activity of antithrombin III, thereby inactivating thrombin (factor IIa) and activated factor X (Xa), and preventing fibrin clot formation. It also inhibits factors IXa, XIa, and XIIa.
25,000 units in 250 mL D5W (100 units/mL) continuous IV infusion at 20,000-40,000 units/24 hours; adjust based on aPTT.
10-100 units/mL solution; flush intermittent intravenous catheters after each use with 1-5 mL; for central venous catheters, use 2-3 mL of 10 units/mL solution; for peripheral catheters, use 1-2 mL of 10 units/mL solution.
None Documented
None Documented
30-150 minutes (dose-dependent, saturable); mean 60-90 min. Prolonged in hepatic/renal impairment and pulmonary embolism.
1-2 hours (dose-dependent; prolonged with higher doses, renal impairment, or in elderly).
Primarily renal (40-60% as unchanged drug) and reticuloendothelial system; small amount biliary/fecal. Clearance is saturable.
Renal (predominantly via reticuloendothelial system and liver metabolism; unchanged drug excreted in urine).
Category A/B
Category C
Anticoagulant
Anticoagulant